Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.

Shaji Kumar,Ravi Vij,Jonathan L. Kaufman,Joseph R. Mikhael,Thierry Facon,Brigitte Pegourie,Lotfi Benboubker,Cristina Gasparetto,Martine Amiot,Philippe Moreau,Susan Diehl,Stefanie Alzate,Jeremy A. Ross,Martin Dunbar,Ming Zhu,Suresh Agarwal,Joel D. Leverson,Paulo Maciag,Maria Verdugo,Cyrille Touzeau

Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.

2016

8032Background: The anti-apoptotic protein BCL-2 has been implicated in the survival of multiple myeloma (MM) cells. Venetoclax (VEN) is an oral, highly selective BCL-2 inhibitor, which induces cel...

Keywords:

Refractory Multiple Myeloma
Oncology
Pathology
Venetoclax
Medicine
Internal medicine
Ven
Multiple myeloma
highly selective
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations